INSURANCE – Adds to existing law to establish the Idaho Prior Authorization Reform Act.
House Bill 841 would create a new chapter in Idaho insurance law called the Idaho Prior Authorization Reform Act. The bill is aimed at health insurance issuers, health benefit plans, dental benefit plans, and utilization review organizations, and it sets detailed rules for how prior authorization must be disclosed, processed, appealed, and reported. It requires insurers to publish current prior authorization requirements and clinical review criteria, give advance notice before adding or changing requirements, and provide statistics on approvals and denials. It also establishes electronic prior authorization interface requirements aligned with federal interoperability standards and sets timelines for standard and expedited decisions.
The bill also limits how long prior authorization approvals remain valid, including special rules for recurring services tied to chronic conditions, and requires insurers to honor certain prior approvals for the first 90 days after a member changes plans. It restricts revocation of approvals except in specified circumstances such as fraud, safety alerts, legal changes, or material changes in clinical circumstances. The Department of Insurance would be given enforcement authority, including cease-and-desist orders, corrective action plans, administrative fines, complaint investigation, and authority over utilization review organizations. The bill also creates a de minimis exemption for insurers that use prior authorization on less than 1% of claims in the prior year, and it bars a private right of action.
This bill would add a substantial new regulatory framework to Title 41 of the Idaho Code governing prior authorization practices in health and dental coverage. It would impose new disclosure, timing, reporting, and appeals obligations on insurers and utilization review organizations, while also creating new consumer and provider protections around continuity of care, approval duration, and notice of denials. The Department of Insurance would gain new oversight and enforcement responsibilities, and insurers would need to align their processes with federal interoperability and CMS prior authorization standards where applicable. The bill expressly excludes self-insured ERISA plans, workers’ compensation, and prescription drugs, biologics, biosimilars, and pharmaceutical medicines from its scope.
No committee transcript or recorded vote information was provided, so the available context does not show direct debate or measured support/opposition. Based on the bill text, the measure appears to be framed as a patient- and provider-protection reform intended to reduce administrative barriers and increase transparency in prior authorization. The overall tone of the legislation is reform-oriented and consumer-protective, with a strong emphasis on access to care and limiting insurer discretion.
The main likely points of contention are the bill’s restrictions on insurer prior authorization practices, including shorter decision deadlines, mandatory disclosure of criteria, limits on revoking approvals, and requirements to honor prior approvals across plan changes. Insurers and utilization review organizations may object to the administrative burden, compliance costs, and reduced flexibility in managing utilization and fraud prevention, while providers and patients are likely to support the added transparency and continuity protections. Another possible area of dispute is the bill’s interaction with federal law and its partial exclusions, especially the carve-out for ERISA self-insured plans and prescription drugs, which may limit the bill’s reach.